tiprankstipranks
Trending News
More News >
Emyria Ltd (AU:EMD)
ASX:EMD
Australian Market

Emyria Ltd (EMD) AI Stock Analysis

Compare
13 Followers

Top Page

AU

Emyria Ltd

(Sydney:EMD)

Rating:44Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
Emyria Ltd's overall stock score of 44 reflects significant financial challenges and valuation concerns. The company's negative earnings, high leverage, and cash flow difficulties are major risk factors. Technical indicators show a lack of strong momentum, further contributing to the cautious outlook.

Emyria Ltd (EMD) vs. iShares MSCI Australia ETF (EWA)

Emyria Ltd Business Overview & Revenue Model

Company DescriptionEmyria Ltd (EMD) is a healthcare technology and drug development company focused on advancing treatments for unmet medical needs through innovative research and clinical trials. The company operates within the healthcare and biotechnology sectors, offering a range of services that include drug development, data analytics, and clinical trials management. Emyria leverages proprietary data and technology to optimize patient outcomes and accelerate the commercialization of new therapies.
How the Company Makes MoneyEmyria Ltd generates revenue primarily through its drug development and clinical trial services. The company's revenue streams include partnerships with pharmaceutical companies for the co-development of new therapies, which often involve milestone payments and royalties from successful commercialization. Emyria also earns income from conducting clinical trials and offering data analytics services to healthcare providers and research institutions. Significant partnerships with leading pharmaceutical firms and research organizations contribute to Emyria's earnings by providing funding and collaborative opportunities in drug development and clinical research.

Emyria Ltd Financial Statement Overview

Summary
Emyria Ltd faces significant financial challenges with declining revenue, negative profit margins, and high leverage. These issues overshadow the modest revenue growth.
Income Statement
35
Negative
Emyria Ltd shows a declining trend in revenue with significant negative gross and net profit margins. The revenue growth rate between 2023 and 2024 is 38.34%, but profitability indicators like EBIT and EBITDA margins are negative, indicating operational challenges.
Balance Sheet
40
Negative
The company has a high debt-to-equity ratio, indicating potential leverage risks. Equity is shrinking, reflecting a decrease in financial stability. Return on Equity (ROE) is negative due to net losses, while the equity ratio is relatively low, suggesting high liabilities compared to assets.
Cash Flow
45
Neutral
Emyria Ltd's cash flow statements show negative operating and free cash flows, although there is some improvement in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow difficulties. Financing activities are helping to offset cash flow issues, but sustainability is a concern.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue1.77M2.20M1.59M1.82M1.98M1.01M
Gross Profit-172.42K-167.55K-3.32M-4.41M-1.58M-2.79M
EBITDA-399.76K-13.03M-4.14M-6.74M-4.49M-4.80M
Net Income-1.63M-11.46M-5.13M-7.33M-4.91M-5.24M
Balance Sheet
Total Assets5.04M5.43M10.16M8.25M9.06M5.06M
Cash, Cash Equivalents and Short-Term Investments1.55M1.57M2.73M3.88M6.53M3.69M
Total Debt802.68K1.72M1.27M632.70K949.70K610.82K
Total Liabilities1.63M3.00M3.37M1.93M1.88M1.28M
Stockholders Equity3.41M2.43M6.79M6.32M7.18M3.78M
Cash Flow
Free Cash Flow-973.65K-4.44M-7.01M-7.46M-4.60M-4.65M
Operating Cash Flow-812.51K-4.28M-3.77M-5.43M-3.94M-4.45M
Investing Cash Flow-1.18M-1.38M-3.23M-2.03M-661.39K-201.81K
Financing Cash Flow1.58M4.50M5.86M4.81M7.44M5.73M

Emyria Ltd Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.03
Price Trends
50DMA
0.03
Positive
100DMA
0.03
Negative
200DMA
0.03
Negative
Market Momentum
MACD
<0.01
Negative
RSI
53.54
Neutral
STOCH
90.79
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EMD, the sentiment is Positive. The current price of 0.03 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.54 is Neutral, neither overbought nor oversold. The STOCH value of 90.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:EMD.

Emyria Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AURHT
64
Neutral
AU$18.38M140.00-3.11%89.13%69.57%
AUPCK
55
Neutral
AU$77.37M-457.46%21.93%10.34%
AUSHG
54
Neutral
AU$113.13M
52
Neutral
$7.50B0.31-61.87%2.27%17.10%1.59%
AUMDR
51
Neutral
AU$34.36M110.00-8.34%-5.27%50.29%
AUIME
47
Neutral
AU$15.83M-17.24%34.47%41.83%
AUEMD
44
Neutral
AU$16.51M-74.80%-9.16%89.23%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:EMD
Emyria Ltd
0.03
-0.03
-50.00%
AU:RHT
Resonance Health Ltd
0.04
-0.02
-33.33%
AU:MDR
MedAdvisor Limited
0.06
-0.44
-88.00%
AU:SHG
Singular Health Group Ltd
0.36
0.27
300.00%
AU:IME
ImExHS Limited
0.30
-0.19
-38.78%
AU:PCK
PainChek Ltd
0.04
0.01
33.33%

Emyria Ltd Corporate Events

Tattarang Ventures Ceases to be Substantial Holder in Emyria
Jun 29, 2025

Emyria Limited has announced that Tattarang Ventures Pty Ltd, along with associated entities, has ceased to be a substantial holder in the company as of June 26, 2025. This change was due to the dilution of shares following the issuance of fully paid ordinary shares pursuant to a placement, affecting 23,817,777 shares. This development may impact Emyria’s shareholder structure and could influence its market positioning and stakeholder interests.

Emyria Limited Issues New Shares to Strengthen Market Position
Jun 26, 2025

Emyria Limited has announced the issuance of 120,206,872 new fully paid ordinary shares at $0.024 per share, which will be immediately tradable under the exemption provided by section 708A(5) of the Corporations Act. This move is part of a strategic placement to enhance the company’s financial position and operational capabilities, potentially impacting its market presence and stakeholder interests positively.

Emyria Ltd Announces Quotation of New Securities on ASX
Jun 26, 2025

Emyria Ltd has announced the quotation of 120,206,872 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of June 26, 2025. This move is part of previously announced transactions and reflects the company’s efforts to enhance its market presence and operational capacity, potentially impacting its stakeholders by increasing liquidity and visibility in the market.

Emyria Secures Landmark Medibank Agreement for PTSD Treatment
Jun 20, 2025

Emyria Limited has announced a landmark reimbursement agreement with Medibank, Australia’s largest private health insurer, which will provide coverage for eligible members with PTSD to access Emyria’s psychiatrist-led program at Perth Clinic. This development, highlighted at the Psychedelic Science 2025 conference, positions Emyria as a global leader in creating sustainable funding pathways for complex mental health care models, addressing significant barriers in scaling psychotherapy models.

Emyria Ltd Announces Strategic Bonus Issue of Securities
Jun 18, 2025

Emyria Ltd has announced a proposed bonus issue of 166,402,206 unquoted options, exercisable at $0.05 each, with an expiration date 18 months from the date of issue. This strategic move is aimed at enhancing shareholder value and strengthening the company’s capital structure, potentially impacting its market position positively.

Emyria Partners with Medibank to Fund PTSD Program, Expanding National Mental Health Care
Jun 18, 2025

Emyria Limited has announced a multi-year agreement with Medibank, Australia’s largest private health insurer, to fund Emyria’s PTSD care program at Perth Clinic. This partnership marks the first major private health insurance funding for a psychotherapy-led PTSD program in Australia, validating Emyria’s Empax Model. The program, which integrates psychiatrist-supervised therapy and real-world data capture, is now accessible to eligible Medibank customers without out-of-pocket costs. This collaboration positions Emyria as a national leader in mental health care and supports its expansion strategy to establish additional centers and partnerships across Australia. The program’s outcomes will be independently evaluated by the Australian National University to support broader adoption and reimbursement.

Emyria Limited Requests Trading Halt Ahead of Major Announcement
Jun 16, 2025

Emyria Limited, a company listed on the Australian Securities Exchange, has requested a trading halt in its securities. This halt is pending the release of an announcement concerning a significant commercial agreement and capital raising. The trading halt is expected to remain in place until either the announcement is made or normal trading resumes on 18 June 2025. This move could have implications for Emyria’s market positioning and stakeholder interests, as it suggests potential strategic developments within the company.

Emyria Reports Promising Six-Month PTSD Treatment Outcomes
May 27, 2025

Emyria Limited has announced promising six-month follow-up results from its treatment program for patients with treatment-resistant PTSD, showing significant symptom improvement and quality-of-life gains. The results highlight the effectiveness of Emyria’s structured, psychiatrist-led care model, which has shown to provide meaningful and sustained improvements in a real-world setting, positioning the company as a global leader in PTSD treatment.

David Pevcic Ceases Substantial Holding in Emyria Ltd
May 19, 2025

Emyria Ltd has announced that David Dominic Pevcic has ceased to be a substantial holder in the company as of March 31, 2025. This change is due to the dilution of shares resulting from a placement, affecting over 20 million voting securities. The announcement reflects a shift in the company’s shareholder structure, which may influence its governance and strategic direction.

Emyria Reports Positive Outcomes and Strategic Expansion
Apr 29, 2025

Emyria Limited reported significant clinical outcomes from its PTSD treatment program, with patients showing substantial improvements in symptoms and quality of life. The company also launched a treatment-resistant depression program, engaged with health funders for pilot programs, restructured its leadership, and expanded its treatment capacity by opening a new Empax Centre.

Emyria Expands Mental Health Services with New Empax Centre
Apr 13, 2025

Emyria Limited has opened its second Empax Centre within Perth Clinic, a leading private mental health hospital in Western Australia, expanding its treatment capacity by 50%. This move is part of a broader strategy to meet growing national demand and align with healthcare funders’ requirements for evidence-based mental health therapies. The new centre will initially treat patients with PTSD and treatment-resistant depression, with plans for further expansion on the East Coast. The initiative reflects Emyria’s commitment to scalable, evidence-based care and its potential for lasting patient impact, supported by private insurers and major payers.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 28, 2025